{"prompt": "['2017N323364_01', 'CONFIDENTIAL', '2019N398531_00', '-', '207626', 'derived from the original SGRQ, and produces scores equivalent to the SGRQ instrument', '[Meguro, 2007].', '9.1.3.', 'COPD Assessment Test (CAT)', 'The CAT will be completed by participants at Screening (Visit 1), Randomisation (Visit', '2), Day 28 (Visit 3), and Day 84 (Visit 4). CAT should be collected prior to SGRQ-C', 'when collected at the same visit.', 'The COPD Assessment Test [Jones, 2009; Jones, 2012] is a validated, short and simple', 'patient completed questionnaire which has been developed for use in routine clinical', 'practice to measure the health status of patients with COPD. The CAT is an 8-item', 'questionnaire suitable for completion by all patients diagnosed with COPD. When', 'completing the questionnaire, participants rate their experience on a 6-point scale,', 'ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-', '40. Higher scores indicate greater disease impact.', '9.1.4.', 'COPD Exacerbations', 'COPD exacerbation data will be collected from the start of the randomised double blind', 'treatment period (Visit 2) until the safety follow up contact at Visit 6. Participants will', 'complete a paper Medical Problems worksheet to record medical problems experienced', 'during the study. This paper worksheet must be reviewed by the Investigator (or', 'designee) at each visit to the study site to assist in the identification of new COPD', 'exacerbations.', 'Every effort should be made to conduct a chest x-ray within 48 hours of identification of', 'a moderate or severe exacerbation.', 'All COPD exacerbations will be recorded on the exacerbation page of the eCRF.', 'Details on COPD Exacerbation Identification, Categorization and Treatment Guidelines', 'are provided in Appendix 5.', '9.2.', 'Adverse Events', 'The definitions of an AE or SAE can be found in Appendix 6', 'The Investigator and any designees are responsible for detecting, documenting, and', 'reporting events that meet the definition of an AE or SAE and remain responsible for', 'following up AEs that are serious, considered related to the study treatment or the study,', 'or that caused the participant to discontinue the study treatment or withdraw from the', 'study (see Section 8).', '63']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', 'Any SAEs assessed as related to study participation (e.g., study treatment,', 'protocol-mandated procedures, or change in existing therapy) or related to a', 'GSK product will be recorded from the time a participant consents to participate', 'in the study up to and including the safety follow-up contact at Visit 6.', 'All AEs will be collected from the start of study treatment (Visit 2) until the', 'safety follow-up contact at the time points specified in the SoA (Section 2).', 'Medical occurrences that begin before the start of study treatment but after', 'obtaining informed consent will be recorded on the Medical History/Current', 'Medical Conditions section of the eCRF not the AE section.', 'All SAEs will be recorded and reported to the sponsor or designee immediately', 'and under no circumstance should this exceed 24 hours, as indicated in', 'Appendix 6. The Investigator will submit any updated SAE data to the sponsor', 'or designee within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'participants. However, if the Investigator learns of any SAE, including a death,', 'at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study treatment or study', 'participation, the Investigator must promptly notify the sponsor or designee.', 'The method of recording, evaluating, and assessing causality of AEs and SAEs', 'and the procedures for completing and transmitting SAE reports are provided in', 'Appendix 6.', '9.2.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AE and/or SAE. Open-ended and', 'non-leading verbal questioning of the participant is the preferred method to inquire about', 'AE occurrence.', 'Participants will be issued with a paper Medical Problems worksheet to record any', 'medical problems experienced during the study. This paper worksheet will be used to', 'assist participant recall in discussions with the Investigator (or designee), for site staff to', 'then enter as appropriate in the eCRF.', '9.2.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the Investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All SAEs will be followed until the event is', 'resolved, stabilized, otherwise explained, or the participant is lost to follow-up (as', 'defined in Section 8.3). Further information on follow-up procedures is given in', 'Appendix 6.', '64']\n\n###\n\n", "completion": "END"}